Evidence map›Paper›PMID 41366119›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

[

Jiarou Wang, Linlin Li, Jingci Chen, Rongxi Wang, Jialin Xiang, Xingtong Peng, Yanwei Wang, Yaping Luo, Lin Zhu, Hank F Kung and 3 more

Registry-linked trialAbstract readComparative StudyValidation Study
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05324332 (A Pilot Comparison of 68Ga-P16-093 and 68Ga-PSMA-11 in the Same Group of Primary Prostate Cancer Patients), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05324332 narecruitingnot on this map

A Pilot Comparison of 68Ga-P16-093 and 68Ga-PSMA-11 in the Same Group of Primary Prostate Cancer Patients

TypeinterventionalSponsorPeking Union Medical College HospitalRan2022 to 2025Enrolled50ConditionsProstate CancerArms68Ga-P16-093, 68Ga-PSMA-11
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Performance of [European journal of nuclear medicine and molecular imaging · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jiarou Wang *Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, 100730, China.
Linlin Li *Department of Nuclear Medicine, Molecular Imaging Lab, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Jingci ChenDepartment of Pathology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
Rongxi WangDepartment of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, 100730, China.
Jialin XiangDepartment of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, 100730, China.
Xingtong PengDepartment of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, 100730, China.
Yanwei WangDepartment of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, 100730, China.
Yaping LuoDepartment of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, 100730, China.
Lin ZhuCollege of Chemistry, Beijing Normal University, Beijing, China.
Hank F KungDepartment of Radiology, University of Pennsylvania, Philadelphia, USA.
Zhien ZhouDepartment of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China. zhouzhien@sina.com.
Yu XiaoDepartment of Pathology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China. xiaoyu7512@gmail.com.
Zhaohui ZhuDepartment of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, 100730, China. 13611093752@163.com.ORCID 0009-0008-7394-9889

Funding

Chinese Academy of Medical Science Innovation Fund for Medical Sciences 2021-I2M-1-016National High-Level Hospital Clinical Research Funding 2022-PUMCH-C-004National High-Level Hospital Clinical Research Funding 2022-PUMCH-D-002National Natural Science Foundation of China 82272046
6 · The paper itself

Abstract

purposeProstate-specific membrane antigen (PSMA) PET/CT enhances prostate cancer (PCa) diagnosis. The newly developed PSMA probe, [

methodsThis prospective study enrolled newly diagnosed PCa patients (April 2022-November 2023). All patients underwent [

resultsFifty-six treatment-naïve male patients (mean age 67 ± 6 years; range 52-77) were prospectively enrolled. A subgroup of 37 patients who underwent both [⁶⁸Ga]Ga-P16-093 and [

conclusion[

trial registrationClinicalTrials.gov, NCT05324332. Registered 04 March 2022. URL OF REGISTRY: https://clinicaltrials.gov/ct2/show/NCT05324332.

Indexed as

DipeptidesEdetic AcidOligopeptidesPositron Emission Tomography Computed TomographyProstatic NeoplasmsAgedGallium IsotopesGallium RadioisotopesHumansMaleMiddle AgedProspective StudiesDipeptidesEdetic Acidgallium 68 PSMA-11Gallium IsotopesGallium RadioisotopesOligopeptidesPSMA-11HistopathologyProstate cancerProstatectomyPSMA PET/CT

Identifiers

PMID41366119

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.